DBV Technologies S.A. - American Depositary Shares — Liquidità (NASDAQ:DBVT)

Financials

Flusso di cassa derivante dalle attività operative -165.61 M-108.24 M-55.67 M-79.65 M-104.47 M-121.18 M -121.18 M Flussi di cassa derivanti dalle attività di investimento -2.87 M-433 K-100 K-808 K-757 K-1.37 M -1.37 M Liquidità derivante dalle attività di finanziamento 149.55 M274 K194.12 M6.77 M587 K276.18 M 276.18 M Liquidità libera -168.37 M-109.16 M-56.42 M-80.33 M-106.81 M-121.72 M -121.71 M

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

DBVT

Financials

DBV Technologies S.A. - American Depositary Shares

Notizie

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know

DBV Technologies: A Tough Nut To Crack In A Shrinking Market (NASDAQ:DBVT)

Cantor Fitzgerald conferma il rating su DBV Technologies per il potenziale del cerotto

Cantor Fitzgerald conferma rating Overweight su azioni DBV Technologies

Citizens alza il target su DBV Technologies per le prospettive del farmaco

Citizens conferma il rating su DBV Technologies per il potenziale di Viaskin Peanut

Citizens reiterates DBV Technologies stock rating on Viaskin Peanut potential

Le azioni di DBV Technologies salgono sui nuovi dati dello studio sul cerotto per le arachidi

DBV Technologies stock surges on new peanut patch trial data

Guggenheim riconferma rating Buy su DBV Technologies con target di $51

Guggenheim reiterates Buy rating on DBV Technologies stock with $51 target